Overview
Adrian Marais practices in Cape Town, South Africa. Mr. Marais is rated as an Experienced expert by MediFind in the treatment of Apolipoprotein C2 Deficiency. His top areas of expertise are High Cholesterol, Familial Hypercholesterolemia, Defective Apolipoprotein B-100, and Hyperlipidemia Type 3.
His clinical research consists of co-authoring 21 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Apolipoprotein C2 Deficiency.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Defective Apolipoprotein B-100Mr. Marais isAdvanced. Learn about Defective Apolipoprotein B-100.
- Familial HypercholesterolemiaMr. Marais isAdvanced. Learn about Familial Hypercholesterolemia.
- High CholesterolMr. Marais isAdvanced. Learn about High Cholesterol.
- Experienced
- Apolipoprotein C2 DeficiencyMr. Marais isExperienced. Learn about Apolipoprotein C2 Deficiency.
- AtherosclerosisMr. Marais isExperienced. Learn about Atherosclerosis.
- Familial HypertriglyceridemiaMr. Marais isExperienced. Learn about Familial Hypertriglyceridemia.
- Familial Lipoprotein Lipase DeficiencyMr. Marais isExperienced. Learn about Familial Lipoprotein Lipase Deficiency.
- Homozygous Familial Hypercholesterolemia (HoFH)
- Hyperlipidemia Type 3Mr. Marais isExperienced. Learn about Hyperlipidemia Type 3.